DK144261C - Medicinsk tablet indeholdende allopurinol - Google Patents
Medicinsk tablet indeholdende allopurinol Download PDFInfo
- Publication number
- DK144261C DK144261C DK280174AA DK280174A DK144261C DK 144261 C DK144261 C DK 144261C DK 280174A A DK280174A A DK 280174AA DK 280174 A DK280174 A DK 280174A DK 144261 C DK144261 C DK 144261C
- Authority
- DK
- Denmark
- Prior art keywords
- allopurinol
- tablet
- tablet according
- weight
- minutes
- Prior art date
Links
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 title claims description 68
- 229960003459 allopurinol Drugs 0.000 title claims description 67
- 239000008187 granular material Substances 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 22
- 239000003979 granulating agent Substances 0.000 claims description 14
- 239000007884 disintegrant Substances 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 230000010354 integration Effects 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 16
- 238000005469 granulation Methods 0.000 description 13
- 230000003179 granulation Effects 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- 229920003110 Primojel Polymers 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000000227 grinding Methods 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- -1 80-90% by weight Chemical compound 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229950002752 oxipurinol Drugs 0.000 description 3
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- XGGAWFDOIDZRPI-UHFFFAOYSA-N 4,6-Dihydroxy Natural products C1=C2OCOC2=CC(C2OC(C3C(OC(O)C32)C=2C=C3OCOC3=CC=2)O)=C1 XGGAWFDOIDZRPI-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2462873 | 1973-05-23 | ||
| GB2462873A GB1460302A (en) | 1973-05-23 | 1973-05-23 | Tablet formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK144261B DK144261B (enrdf_load_html_response) | 1982-02-01 |
| DK144261C true DK144261C (da) | 1991-02-04 |
Family
ID=10214700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK280174AA DK144261C (da) | 1973-05-23 | 1974-05-22 | Medicinsk tablet indeholdende allopurinol |
Country Status (21)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1533243A (en) * | 1975-02-13 | 1978-11-22 | Wellcome Found | Tablet formulation |
| US4143129A (en) | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
| US4115563A (en) * | 1977-03-14 | 1978-09-19 | Sterling Drug Inc. | Pharmaceutical steroid formulation |
| GB1601833A (en) * | 1978-02-06 | 1981-11-04 | Wellcome Found | Antacid formulation |
| DE3839825A1 (de) * | 1988-11-25 | 1990-06-13 | Henning Berlin Gmbh | Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze |
| EP0719547A1 (en) * | 1994-07-18 | 1996-07-03 | Luis Cipriano Carvajal Martin | Self-desintegrating compact granules used in galenic forms and containing active insoluble or hardly soluble principles |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB975850A (en) * | 1955-08-10 | 1964-11-18 | Wellcome Found | Xanthine oxidase inhibitors |
| US3624205A (en) * | 1967-04-25 | 1971-11-30 | Burroughs Wellcome Co | Treatment of hyperuricemia in humans |
-
1973
- 1973-05-23 GB GB2462873A patent/GB1460302A/en not_active Expired
-
1974
- 1974-05-22 AU AU69252/74A patent/AU469472B2/en not_active Expired
- 1974-05-22 SE SE7406864A patent/SE402525C/sv not_active IP Right Cessation
- 1974-05-22 BE BE144636A patent/BE815409A/xx not_active IP Right Cessation
- 1974-05-22 HU HUWE507A patent/HU170656B/hu unknown
- 1974-05-22 JP JP5776774A patent/JPS577128B2/ja not_active Expired
- 1974-05-22 AT AT426774A patent/AT351167B/de not_active IP Right Cessation
- 1974-05-22 ZA ZA00743318A patent/ZA743318B/xx unknown
- 1974-05-22 IE IE1097/74A patent/IE39283B1/xx unknown
- 1974-05-22 FR FR7417820A patent/FR2230341B1/fr not_active Expired
- 1974-05-22 DE DE19742424950 patent/DE2424950A1/de active Pending
- 1974-05-22 NL NLAANVRAGE7406873,A patent/NL190436C/xx not_active IP Right Cessation
- 1974-05-22 FI FI1566/74A patent/FI156674A7/fi unknown
- 1974-05-22 IL IL44877A patent/IL44877A/en unknown
- 1974-05-22 CA CA200,536A patent/CA977279A/en not_active Expired
- 1974-05-22 DK DK280174AA patent/DK144261C/da not_active IP Right Cessation
- 1974-05-23 CY CY941A patent/CY941A/xx unknown
- 1974-12-02 KE KE2808A patent/KE2808A/xx unknown
-
1978
- 1978-01-05 HK HK13/78A patent/HK1378A/xx unknown
- 1978-12-31 MY MY1978181A patent/MY7800181A/xx unknown
-
1980
- 1980-06-13 IT IT8048966A patent/IT8048966A0/it unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB975850A (en) * | 1955-08-10 | 1964-11-18 | Wellcome Found | Xanthine oxidase inhibitors |
| US3497307A (en) * | 1955-08-10 | 1970-02-24 | Burroughs Wellcome Co | Method of preventing oxidation of 6-substituted purines with 4-hydroxy-1h-pyrazolo(3,4-d)pyrimidine and 4,6 - dihydroxy-1h-pyrazolo(3,4-d)pyrimidine |
| US3624205A (en) * | 1967-04-25 | 1971-11-30 | Burroughs Wellcome Co | Treatment of hyperuricemia in humans |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960009182B1 (ko) | 제약정제, 제약과립 및 그의 제조방법 | |
| DK175627B1 (da) | Farmaceutisk præparat til oral indgift med reguleret afgivelse og forlænget virkning | |
| NL8601961A (nl) | Granulaire vorm van farmaceutisch werkzame stoffen met vertraagde afgifte. | |
| NO174876B (no) | Fremgangsmåte for fremstilling av et medikament i form av granuler basert på fenofibrat, innbefattende en inert kjerne | |
| JP2012211202A (ja) | 医薬組成物 | |
| NO328152B1 (no) | Glyburid og glyburid-preparater samt anvendelse av disse for fremstilling av medikament for behandling av sykdom | |
| US20060240101A1 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| NO175884B (no) | Fremgangsmåte for fremstilling av en presset tablett som inneholder methylprednisolon og et super-desintegrasjonsmiddel | |
| Alhalmi et al. | Sustained release matrix system: an overview | |
| NO157805B (no) | Fremgangsmaate for fremstilling av et preparat for behandling av urinveisinfeksjoner. | |
| CN100490797C (zh) | 药物组合物 | |
| JP2005520785A (ja) | ルミラコキシブ含有医薬組成物 | |
| DK144261C (da) | Medicinsk tablet indeholdende allopurinol | |
| CN108201529B (zh) | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 | |
| AU2002213900A1 (en) | Pharmaceutical compositions | |
| NL8302416A (nl) | Vertraagd werkend geneesmiddel met daarin suloctidil. | |
| Ohmori et al. | Characteristics of erythritol and formulation of a novel coating with erythritol termed thin-layer sugarless coating | |
| EP3345626A1 (en) | Super-rapid disintegrating tablet, and method for producing same | |
| CN101219122A (zh) | 盐酸吡格列酮分散片及其制备方法 | |
| NL8402128A (nl) | Werkwijze ter bereiding van een preparaat van indomethacine of niomethacine met retard-werking. | |
| JP2013023463A (ja) | 生理活性物質含有粒子の製造方法 | |
| CN107441051B (zh) | 一种盐酸普罗帕酮微片及其制备方法 | |
| NO774400L (no) | Fremgangsmaate til fremstilling av farmasoeytiske sammensetninger | |
| RU2145213C1 (ru) | Фармацевтическая композиция, обладающая ноотропным действием, и способ ее получения | |
| Sharma et al. | A Review on Fast Dissolving Tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |